Clinical Utility of Combined Tissue and Plasma Next-Generation Sequencing in Patients With Advanced, Treatment-Naïve NSCLC

Overview

Journal JTO Clin Res Rep

Date 2025 Feb 25

PMID 39996090

Authors

Helena Bote-de Cabo

Marco Siringo

Esther Conde

Susana Hernandez

Fernando Lopez-Rios

Alicia Castelo-Loureiro

Esther Garcia-Lorenzo

Javier Baena

Mercedes Herrera

Ana Belen Enguita

Yolanda Ruano

Jon Zugazagoitia

Luis Paz-Ares

Affiliations

Soon will be listed here.

Abstract

Introduction: Tissue and plasma-based next-generation sequencing (NGS) have complementary roles in patients with advanced NSCLC. Nevertheless, whether there is any added clinical value in combining both methods in the treatment of naïve patients remains unclear.

Methods: We retrospectively collected clinical and genomic data from 275 patients with treatment-naïve advanced NSCLC who had undergone plasma-based NGS at diagnosis in our institution. We analyzed patient data in two separate cohorts, each assessed with a different plasma-based NGS method: cohort 1 (n = 127, Guardant360), and cohort 2 (n = 148, FoundationACT/FoundationOne Liquid CDx). Ninety-five patients (75%) in cohort 1 and 108 patients (73%) in cohort 2 underwent concurrent amplicon-based tissue NGS testing locally.

Results: Forty-three patients in cohort 1 (34%) and 49 patients in cohort 2 (33%) harbored European Society for Medical Oncology Scale for Clinical Actionability of Molecular Targets (ESCAT) I or II targetable driver alterations. The addition of orthogonal biopsy (tissue to liquid, or liquid to tissue) offered no relevant clinical value in cases with ESCAT I or II targetable drivers already detected by one method. In contrast, adding orthogonal biopsy incremented the detection of ESCAT I or II targetable drivers not only in cases with uninformative testing (undetectable circulating tumor DNA, unavailable/inadequate tissue) but also in about 5% of the patients with seemingly informative but driver undetected molecular results. The prevalence of ESCAT I or II targetable drivers in plasma was significantly higher in patients with adenocarcinoma, 20 pack-year or less smoking history, and abdominal metastases.

Conclusions: Our study suggests that the addition of sequential orthogonal biopsy should be considered whenever an ESCAT I or II targetable driver has not been detected by the initial method, including cases with seemingly informative molecular analysis.

References

Kalemkerian G, Narula N, Kennedy E, Biermann W, Donington J, Leighl N . Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association.... J Clin Oncol. 2018; 36(9):911-919. DOI: 10.1200/JCO.2017.76.7293. View

Rolfo C, Madison R, Pasquina L, Brown D, Huang Y, Hughes J . Measurement of ctDNA Tumor Fraction Identifies Informative Negative Liquid Biopsy Results and Informs Value of Tissue Confirmation. Clin Cancer Res. 2024; 30(11):2452-2460. PMC: 11145175. DOI: 10.1158/1078-0432.CCR-23-3321. View

Lee Y, Clark E, Milan M, Champagne C, Michael K, Awad M . Turnaround Time of Plasma Next-Generation Sequencing in Thoracic Oncology Patients: A Quality Improvement Analysis. JCO Precis Oncol. 2020; 4. PMC: 7529535. DOI: 10.1200/PO.20.00121. View

Rolfo C, Mack P, Scagliotti G, Aggarwal C, Arcila M, Barlesi F . Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer. J Thorac Oncol. 2021; 16(10):1647-1662. DOI: 10.1016/j.jtho.2021.06.017. View

Cescon D, Bratman S, Chan S, Siu L . Circulating tumor DNA and liquid biopsy in oncology. Nat Cancer. 2022; 1(3):276-290. DOI: 10.1038/s43018-020-0043-5. View

Leighl N, Page R, Raymond V, Daniel D, Divers S, Reckamp K . Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-small Cell Lung Cancer. Clin Cancer Res. 2019; 25(15):4691-4700. DOI: 10.1158/1078-0432.CCR-19-0624. View

Hu Y, Ulrich B, Supplee J, Kuang Y, Lizotte P, Feeney N . False-Positive Plasma Genotyping Due to Clonal Hematopoiesis. Clin Cancer Res. 2018; 24(18):4437-4443. DOI: 10.1158/1078-0432.CCR-18-0143. View

Tomasik B, Skrzypski M, Bienkowski M, Dziadziuszko R, Jassem J . Current and future applications of liquid biopsy in non-small-cell lung cancer-a narrative review. Transl Lung Cancer Res. 2023; 12(3):594-614. PMC: 10087994. DOI: 10.21037/tlcr-22-742. View

Lam V, Zhang J, Wu C, Tran H, Li L, Diao L . Genotype-Specific Differences in Circulating Tumor DNA Levels in Advanced NSCLC. J Thorac Oncol. 2021; 16(4):601-609. PMC: 8012216. DOI: 10.1016/j.jtho.2020.12.011. View

10.

Jordan E, Kim H, Arcila M, Barron D, Chakravarty D, Gao J . Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies. Cancer Discov. 2017; 7(6):596-609. PMC: 5482929. DOI: 10.1158/2159-8290.CD-16-1337. View

11.

Tan A, Tan D . Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations. J Clin Oncol. 2022; 40(6):611-625. DOI: 10.1200/JCO.21.01626. View

12.

Pritchett M, Camidge D, Patel M, Khatri J, Boniol S, Friedman E . Prospective Clinical Validation of the InVisionFirst-Lung Circulating Tumor DNA Assay for Molecular Profiling of Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2020; 3. PMC: 7450945. DOI: 10.1200/PO.18.00299. View

13.

Lockwood C, Borsu L, Cankovic M, Earle J, Gocke C, Hameed M . Recommendations for Cell-Free DNA Assay Validations: A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists. J Mol Diagn. 2023; 25(12):876-897. DOI: 10.1016/j.jmoldx.2023.09.004. View

14.

Zugazagoitia J, Ramos I, Trigo J, Palka M, Gomez-Rueda A, Jantus-Lewintre E . Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping. Ann Oncol. 2018; 30(2):290-296. DOI: 10.1093/annonc/mdy512. View

15.

Makarem M, Leighl N . Molecular testing for lung adenocarcinoma: Is it time to adopt a "plasma-first" approach?. Cancer. 2020; 126(14):3176-3180. DOI: 10.1002/cncr.32875. View

16.

Palmero R, Taus A, Viteri S, Majem M, Carcereny E, Garde-Noguera J . Biomarker Discovery and Outcomes for Comprehensive Cell-Free Circulating Tumor DNA Versus Standard-of-Care Tissue Testing in Advanced Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2022; 5:93-102. DOI: 10.1200/PO.20.00241. View

17.

Swalduz A, Schiffler C, Curcio H, Ambasager B, Le Moel G, Debieuvre D . LIBELULE: A Randomized Phase III Study to Evaluate the Clinical Relevance of Early Liquid Biopsy in Patients With Suspicious Metastatic Lung Cancer. J Thorac Oncol. 2024; . DOI: 10.1016/j.jtho.2024.12.011. View

18.

Cui W, Milner-Watts C, OSullivan H, Lyons H, Minchom A, Bhosle J . Up-front cell-free DNA next generation sequencing improves target identification in UK first line advanced non-small cell lung cancer (NSCLC) patients. Eur J Cancer. 2022; 171:44-54. DOI: 10.1016/j.ejca.2022.05.012. View

19.

Genovese G, Kahler A, Handsaker R, Lindberg J, Rose S, Bakhoum S . Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014; 371(26):2477-87. PMC: 4290021. DOI: 10.1056/NEJMoa1409405. View

20.

Page R, Drusbosky L, Dada H, Raymond V, Daniel D, Divers S . Clinical Outcomes for Plasma-Based Comprehensive Genomic Profiling Versus Standard-of-Care Tissue Testing in Advanced Non-Small Cell Lung Cancer. Clin Lung Cancer. 2021; 23(1):72-81. DOI: 10.1016/j.cllc.2021.10.001. View